TM 2011 Immunization Recommendations H. Cody Meissner, M.D. Professor of Pediatrics Tufts University School of Medicine Boston Floating Hospital for Children Tufts Medical Center TM Prepared for your next patient.
TM Disclaimers Statements and opinions expressed are those of the author and not necessarily those of the American Academy of Pediatrics. Mead Johnson sponsors programs such as this to give healthcare professionals access to scientific and educational information provided by experts. The presenter has complete and independent control over the planning and content of the presentation, and is not receiving any compensation from Mead Johnson for this presentation. The presenter’s comments and opinions are not necessarily those of Mead Johnson. In the event that the presentation contains statements about uses of drugs that are not within the drugs' approved indications, Mead Johnson does not promote the use of any drug for indications outside the FDA-approved product label.
TM Considerations which Influence the Age at which a Vaccine is Recommended Age-specific risk of a disease Immune response to vaccine Interference by maternal antibody Waning immunity Programmatic issues “Crowding of the schedule”
TM Use of Tetanus and Diphtheria and Acellular Pertussis (Tdap) Vaccines Removal of interval between Tdap and tetanus or diphtheria toxoid containing vaccine Use of Tdap in certain adults ≥65 years of age Use of Tdap in under-vaccinated children 7 through 10 years of age
TM Changes to the Meningococcal Conjugate Vaccine Schedule Booster dose Routine vaccination at 11 through 12 years with booster dose at 16 through 21 years If first dose at 13 through 15 years, booster dose preferred at 16 through 18 years Persons 2 through 54 years at increased risk of meningococcal disease should receive a 2 dose primary series (2 months apart), then booster dose every 5 years
TM 13 Valent Pneumococcal Conjugate Vaccine (PCV13) Recommendations PCV13 recommended for all children 2 through 59 months A 4 dose series at 2,4,6 and 12 through 15 months Complete series with PCV13 if begun with PCV7 Supplemental dose of PCV13 for children months who completed PCV7 schedule Supplemental dose of PCV13 for children 60 through 71 months after PCV7 schedule if increased risk
TM Influenza Vaccine Recommendations Routine vaccination of all persons ≥6 months with emphasis on high risk groups For children 6 months through 8 years If vaccinated for 1 st time, 2 doses needed If only 1 dose of seasonal vaccine in and none in previous years, then 2 doses needed If no doses of novel H1N1 last year, then 2 doses needed Healthy, non-pregnant persons 2 through 49 years can receive TIV or LAIV
TM HPV Vaccine Recommendations Quadrivalent HPV vaccine (HPV4) or bivalent (HPV2) vaccine recommended for prevention of cervical precancers and cancers in females HPV4 recommended for prevention of precancers, cancers and genital warts in females HPV4 may be administered to males to reduce risk of genital warts
TM Haemophilus influenzae type b Vaccine For people ≥5 years at increased risk of infection, one dose should be considered Sickle cell disease Leukemia HIV infection Lack a spleen
TM Hepatitis B Vaccine For infants who do not receive a birth dose: Administer 3 doses of HepB on a schedule of 0, 1 and 6 months The final (3 rd or 4 th ) dose in the HepB series should be administered no earlier than age 24 weeks
TM For more information…. On this topic and a host of other topics, visit Pediatric Care Online is a convenient electronic resource for immediate expert help with virtually every pediatric clinical information need. Must-have resources are included in a comprehensive reference library and time-saving clinical tools.. Haven't activated your Pediatric Care Online trial subscription yet? It's quick and easy: simply follow the steps on the back of the card you received from your Mead Johnson representative. Haven't received your free trial card? Contact your Mead Johnson representative or call 888/ today.